At a glance
- Thymogen is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 98 publications mentioning it, including 4 randomized controlled trials and 37 animal-only studies.
- ClinicalTrials.gov lists 4 registered studies testing it (0 active).
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats.
- The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples.
- Reparative and Antioxidant Effects of New Analogues of Immunomodulator Thymogen in Experimental Model of Liver Damage.
- Metal-free sp2 -C7-H Borylation of Tryptophan Containing Peptides and Late-stage Modification.
- Treatments for AIDS/HIV-related Kaposi sarcoma: A systematic review of the literature.
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.
- Characterization of tryptophan-containing dipeptides for anti-angiogenic effects.
- [Age features of bioregulatory therapy of dental diseases.].
- Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity. II. Hemosuppressor activity of 2,5-diketopiperazine-based cyclopeptides.
- Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 4
- Active
- 0
- With posted results
- 0
Conditions studied
| Study | Status | Phase | Start |
|---|---|---|---|
| Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer | Unknown status | Phase 2 | Jan 2001 |
| Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer | Terminated | Phase 2 | Nov 1999 |
| IM-862 in Treating Patients With Recurrent Ovarian Cancer | Completed | Phase 1 | Feb 1999 |
| Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients | Completed | Phase 3 | — |
All 4 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.